Is KPRX or KROS more undervalued in 2026?

CirclFi compares Kiora Pharmaceuticals, Inc. (KPRX) and Keros Therapeutics, Inc. (KROS) using 13 institutional-grade valuation models. KPRX has a Quality of Company score of 5.5/10 while KROS scores 8.6/10.

Which is a better buy — KPRX or KROS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KPRX and KROS valuations compare?

KPRX at $2.68 and KROS at $11.25 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KPRX vs KROS Valuation Comparison 2026 — Intrinsic Value Analysis

KPRX

Pharmaceutical Preparations

Kiora Pharmaceuticals, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$2.68

Last close

Models

8/13

Active

KROS

Pharmaceutical Preparations

Keros Therapeutics, Inc.

Quality

8.6

out of 10

Value Trap

SAFE

Price

$11.25

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	KPRX Fair Value	KPRX Upside	KROS Fair Value	KROS Upside
Bayesian DCF	Intrinsic	$2.01	-24.8%	—	—
Earnings Power Value	Intrinsic	—	—	$40.29	+258.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.48	-80.2%	$56.18	+399.4%
Dynamic NAV	Asset-Based	$4.83	+80.3%	$20.22	+79.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KPRX vs KROS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KPRX vs KROS — Which Stock Is More Undervalued?

KROS scores higher with a 8.6/10 quality rating vs KPRX's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kiora Pharmaceuticals, Inc. (KPRX) and Keros Therapeutics, Inc. (KROS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KPRX currently trades at $2.68 with a QOC of 5.5/10, while KROS trades at $11.25 with a QOC of 8.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).